Gabriele Zucca
unread,Nov 14, 2024, 5:24:28 PM11/14/24Sign in to reply to author
Sign in to forward
You do not have permission to delete messages in this group
Either email addresses are anonymous for this group or you need the view member email addresses permission to view the original message
to HGVS Nomenclature
Dear HGVS Nomenclature group,
I have a question regarding the nomenclature of a variant that is described in an article by Lorenzini et al. (PMID: 32278790). In particular, the authors found a variant in NFKB1 that they describe (Table S1, variant #28) as a deletion (c.950_964del, p.(Pro317_Ile322delinsLeu)) followed by a substitution (c.967A>T, p.(Asn323Tyr)). It is not specified in the table, but I assume the two changes are in cis. According to my understanding, the variant should be described as "c.[950_964del;967A>T]" for the DNA change and "p.[(Pro317_Ile322delinsLeu);(Asn323Tyr)]" for the protein change, given that there are two "normal" TT nucleotides between the deletion and the T-to-A substitution. When I enter the "c" variant in Mutalyzer, however, it normalizes it as "c.950_967delinsTTT" and "p.(Pro317_Asn323delinsLeuTyr)". I kindly ask you which version is correct. Additionally, I think that, on the HGVS Nomenclature website, it could be useful to specify whenever, when a deletion/insertion/duplication is followed by another variant, the position for the second variant should refer the position in the original sequence or in the sequence "modified" by the first variant. Thanks in advance.
Best regards,
Gabriele Zucca, MD.
Screenshot_2024-11-14_23-13-46.png